La prescription de la contraception : « quand le post-partum s’en mêle »

ObjectifsAvec la diminution de la durée de séjours en maternité, une organisation de la sortie en anténatale est préconisée par la HAS. L’objectif de cette étude est d’identifier les facteurs pouvant influencer la qualité de prescription d’une méthode contraceptive lors du séjour en maternité et identifier les actions pouvant être mise en oeuvre pour une prescription optimale de la contraception du post-partum.Matériel et méthodeUne étude prospective multicentrique à visée descriptive a été réalisée au sein de deux maternités de l’agglomération rouennaise. Au total, 111 questionnaires ont été exploité.Résultats58% des patientes avaient reçu une information anténatale sur la contraception du post-partum. Il n’y a pas de sortie précoce observé durant l’étude et 54% des sorties ont été réalisés à J4. 29% de femmes ont eu une méthode contraceptive imposée et 58% des patientes souhaitent changer de méthode à posteriori. Il existe un lien significatif entre le choix de la méthode et la reprise de celle-ci, la satisfaction ou le souhait de changer de méthode contraceptive. Un manque d’informations durant l’entretien de contraception a été observé. La mise en place de brochure et/ou réunions d’informations couplées à l’information du praticien pourrait être efficace en anté- ou post-natal.ConclusionAdapter l’entretien de contraception aux modes de vie et besoin des patientes permettrait la réflexion et le choix libre et éclairé, ainsi que l’observance et la satisfaction à posteriori

Osteoactivin inhibition of osteoclastogenesis is mediated through CD44-ERK signaling

Osteoactivin is a heavily glycosylated protein shown to have a role in bone remodeling. Previous studies from our lab have shown that mutation in Osteoactivin enhances osteoclast differentiation but inhibits their function. To date, a classical receptor and a signaling pathway for Osteoactivin-mediated osteoclast inhibition has not yet been characterized. In this study, we examined the role of Osteoactivin treatment on osteoclastogenesis using bone marrow-derived osteoclast progenitor cells and identify a signaling pathway relating to Osteoactivin function. We reveal that recombinant Osteoactivin treatment inhibited osteoclast differentiation in a dose-dependent manner shown by qPCR, TRAP staining, activity and count. Using several approaches, we show that Osteoactivin binds CD44 in osteoclasts. Furthermore, recombinant Osteoactivin treatment inhibited ERK phosphorylation in a CD44-dependent manner. Finally, we examined the role of Osteoactivin on receptor activator of nuclear factor-κ B ligand (RANKL)-induced osteolysis in vivo. Our data indicate that recombinant Osteoactivin inhibits RANKL-induced osteolysis in vivo and this effect is CD44-dependent. Overall, our data indicate that Osteoactivin is a negative regulator of osteoclastogenesis in vitro and in vivo and that this process is regulated through CD44 and ERK activation

Methods and insights from the characterization of osteoprogenitor cells of bats (Mammalia: Chiroptera)

Osteoprogenitor cells contribute to the development and maintenance of skeletal tissues. Bats are unique model taxa whose cellular processes are poorly understood, especially in regards to skeletal biology. Forelimb bones of bats, unlike those of terrestrial mammals, bend during flight and function in controlled deformation. As a first step towards understanding the molecular processes governing deposition of this flexible bone matrix, we provide the first method for isolation and differentiation of cell populations derived from the bone marrow and cortical bone of bats, and compare results with those harvested from C57BL/6J mice. Osteogenic capacity of these cells was assessed via absolute quantitative real-time PCR (qPCR) and through quantification of in vitro mineral deposition. Results indicate the differentiated bone cells of bats display significantly lower gene expression of known osteogenic markers (Runt-related transcription factor (RUNX2), osteocalcin (BGLAP) and osterix (SP7)), and deposit a less-mineralized matrix compared with murine controls. By characterizing the in vitro performance of osteoprogenitor cells throughout differentiation and matrix production, this study lays the ground work for in vitro manipulations of bat stem and osteoprogenitor cells and extends our understanding of the cellular diversity across mammals that occupy different habitats

Additional file 1: Figure S1. of A direct interaction between NQO1 and a chemotherapeutic dimeric naphthoquinone

The chemical structure of E6a (3-bromo-3′-hydroxy-2,2′-binaphthalenyl-1,4,1′,4′-tetraone). (PNG 40 kb

Additional file 3: Figure S3. of A direct interaction between NQO1 and a chemotherapeutic dimeric naphthoquinone

Two dimers of E6a bound hNQO1 structure showing the loop 230–236 interacting with the active site of neighboring dimer. The FAD molecules are shown in stick representation in each active site. The E6a molecule is shown in ball-and-stick representation. (PNG 2799 kb